ASH 2022 | Phase II study of inotuzumab ozogamicin in MRD+ B-ALL
Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, describes the results of a Phase II study assessing inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia (B-ALL) who are measurable residual disease (MRD)-positive. The study reported that lower doses of fractionated inotuzumab ozogamicin is a well-tolerated option for MRD+ patients, including those with prior exposure to blinatumomab. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Other: Advisory Role, Research Funding; Genentech: Other: Advisory Role, Research Funding; Adaptive Biotechnologies: Other: Advisory Role, Research Funding; Spectrum: Research Funding; Pfizer: Other: Advisory Role, Research Funding; Bristol Myers Squibb: Other: Advisory Role, Research Funding; Amgen: Other: Advisory Role, Research Funding; AbbVie: Other: Advisory Role, Research Funding.
